Advanced in Virilizing Ovarian Tumor

Dr. John H. Farley

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Sjhmc Physician Services
500 W Thomas Rd, 680 Dhmg St Joseph's Pelvi, 
Phoenix, AZ 
Accepting New Patients
Offers Telehealth
Advanced in Virilizing Ovarian Tumor
Sjhmc Physician Services
500 W Thomas Rd, 680 Dhmg St Joseph's Pelvi, 
Phoenix, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Farley is a Gynecologic Oncologist and an Oncologist in Phoenix, Arizona. Dr. Farley is rated as an Advanced provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Ovarian Cancer, Ovarian Carcinosarcoma, Testicular Yolk Sac Tumor, Lymphadenectomy, and Hysterectomy. Dr. Farley is currently accepting new patients.

His clinical research consists of co-authoring 74 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in AZ
Hospital Affiliations
Western Regional Medical Center
St. Joseph's Hospital And Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MercyCare
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

SJHMC PHYSICIAN SERVICES
500 W Thomas Rd, 680 Dhmg St Joseph's Pelvi, Phoenix, AZ 85013

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Enrollment Status: Completed
Publish Date: May 23, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Cisplatin
Study Phase: Phase 3
Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (≤ 2CM) Cervical Cancer
Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (≤ 2CM) Cervical Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 03, 2024
Intervention Type: Other, Procedure
Study Phase: Not Applicable
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer
Enrollment Status: Completed
Publish Date: July 25, 2023
Intervention Type: Drug
Study Drug: Tisotumab Vedotin
Study Phase: Phase 2
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Drug
Study Drugs: VB-111, Paclitaxel
Study Phase: Phase 3
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
Enrollment Status: Completed
Publish Date: August 12, 2022
Intervention Type: Other, Drug, Biological
Study Drugs: Dactinomycin, Leucovorin Calcium, Methotrexate
Study Phase: Phase 3
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Enrollment Status: Unknown
Publish Date: September 30, 2021
Intervention Type: Other, Drug
Study Drugs: Carboplatin, Metformin hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
A Phase II Trial of AZD6244 (NSC# 748727) in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Phase II Trial of AZD6244 (NSC# 748727) in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Completed
Publish Date: December 03, 2020
Intervention Type: Drug, Other
Study Phase: Phase 2
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women With Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum
A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women With Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum
Enrollment Status: Completed
Publish Date: March 10, 2020
Intervention Type: Drug, Other
Study Phase: Phase 2
View 9 Less Clinical Trials

74 Total Publications

Identifying and breaking barriers: Addressing disparities in the care of patients with gynecologic cancers.
Identifying and breaking barriers: Addressing disparities in the care of patients with gynecologic cancers.
Journal: Gynecologic oncology reports
Published: May 12, 2025
Similar Doctors
Distinguished in Virilizing Ovarian Tumor
Dr. Mike F. Janicek
Gynecologic Oncology | Oncology
Distinguished in Virilizing Ovarian Tumor
Dr. Mike F. Janicek
Gynecologic Oncology | Oncology

Honorhealth Ambulatory

10197 N 92nd St, Suite 101, 
Scottsdale, AZ 
 (13.4 miles away)
480-270-5309
Languages Spoken:
English, German
See accepted insurances
Accepting New Patients
Offers Telehealth

Mike Janicek is a Gynecologic Oncologist and an Oncologist in Scottsdale, Arizona. Dr. Janicek is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Sertoli-Leydig Cell Tumor, Ovarian Carcinosarcoma, Ovarian Cancer, Oophorectomy, and Hernia Surgery. Dr. Janicek is currently accepting new patients.

Distinguished in Virilizing Ovarian Tumor
Dr. Ivor B. Benjamin
Gynecologic Oncology | Obstetrics and Gynecology
Distinguished in Virilizing Ovarian Tumor
Dr. Ivor B. Benjamin
Gynecologic Oncology | Obstetrics and Gynecology

Honorhealth Ambulatory

19636 N 27th Ave, Suite 201, 
Phoenix, AZ 
 (12.9 miles away)
623-516-4400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ivor Benjamin is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Phoenix, Arizona. Dr. Benjamin is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Ovarian Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Oophorectomy, and Hysterectomy. Dr. Benjamin is currently accepting new patients.

Distinguished in Virilizing Ovarian Tumor
Dr. Snehal M. Bhoola
Gynecologic Oncology | Obstetrics and Gynecology | Oncology
Distinguished in Virilizing Ovarian Tumor
Dr. Snehal M. Bhoola
Gynecologic Oncology | Obstetrics and Gynecology | Oncology

City Of Hope Medical Group Of Arizona LLC

14200 W Celebrate Life Way, 
Goodyear, AZ 
 (16.5 miles away)
623-207-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Snehal Bhoola is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Goodyear, Arizona. Dr. Bhoola is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Endometrial Cancer, Malignant Mixed Mullerian Tumor, Endometrial Stromal Sarcoma, Bladder Reconstruction, and Oophorectomy. Dr. Bhoola is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Farley's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 16 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile